CETP
Signaling Pathway Map
Research Area
Inhibitory Selectivity
CETP Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2748 |
Anacetrapib (MK-0859)Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3. |
||
| S2792 |
TorcetrapibTorcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3. |
||
| S2925 |
Evacetrapib (LY2484595)Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. |
||
| S2772 |
Dalcetrapib (JTT-705)Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. Phase 3. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2748 |
Anacetrapib (MK-0859)Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3. |
||
| S2792 |
TorcetrapibTorcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3. |
||
| S2925 |
Evacetrapib (LY2484595)Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. Phase 3. |
||
| S2772 |
Dalcetrapib (JTT-705)Dalcetrapib (JTT-705) is a rhCETP inhibitor with IC50 of 0.2 μM that increases the plasma HDL cholesterol. Phase 3. |
